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Detection of Antibodies to Melanocytes in Vitiligo by Specific 
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Immunoprecipitation was used to assay for antibodies 
to normal human melanocytes in the sera of 12 patients 
with common vitiligo and 12 normal individuals. The 
procedure is based on the specific immunoprecipitation 
using protein A-sepharose of antibodies binding to de-
tergent-soluble, radioiodinated macromolecules of nor-
mal human melanocytes grown in culture. Antibodies to 
melanocytes were found in all 12 patients with vitiligo 
but in none of the normal sera. None of the sera reacted 
specifically to normal human fibroblasts or to human 
melanoma cells radioiodinated in a similar manner. 
These observations suggest that antibodies to melano-
cyte-associated antigens are present in common vitiligo. 
Vitiligo is characterized by destruction of melanocytes and 
loss of pigmentation. Although the cause of vitiligo is unknown, 
it is suspected to be an autoimmune disease since it is frequently 
assoc iated with disorders of the immune system [1) and the 
presence of autoantibodies to various organs [2- 4]. However , 
prior reports of antibodies to melanocytes in vitiligo [5- 7) either 
have not been confirmed [8) or have been found to result from 
other diseases concurrently aff1icting the patients [9). 
In this study an immunoprecipitation assay was used to look 
for antibodies to melanocytes in common vitiligo. It was found 
that sera from patients with vitiligo specifically bind detergent-
so luble radioiodinated macromolecules of normal human me-
lanocytes but do not bind macromolecules of normal human 
fibroblasts or human melanoma cells radioiodinated in an 
identica l manner. The results suggest that antibodies to melan-
ocyte-associated antigens occur in individua ls with common 
vitiligo. 
MATERIALS AND METHODS 
S era 
Sera were collected from 12 patients with common viti ligo and no 
evidence of other autoimmune disorders, including mucocutaneous 
candidiasis (MCC). All patients had active disease as evidenced by 
progress ive areas of depigmentation. Sera from 12 age-matched indi-
viduals with no pigmentary diseases were used as controls. 
Cells 
Huma n melanocytes were established and maintained in culture as 
recently desc ribed [10]. Fibroblasts and melanoma cells were grown in 
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Abbrev iations: 
HBSS: Hanks' balanced salt solution 
MCC: mucocutaneous candidiasis 
PBS: phosphate-buffered sa lin e 
plastic culture dishes in RPMI 1640 medium supplemented with 10% 
fetal calf serum and 0.02 mg/ml each of gentamycin, spectinomycin, 
and penicillin . All cells were used when forming confluent cultures. 
Radioiodination 
Surface macromolecules on melanocytes and control cells were ra· 
dio iodinated by the lactoperoxidase method [11] . The method used in 
our laboratory has been previously described [12]. Brielly, cells were 
collected gently with a rubber policema n, washed 3 times with 15 ml of 
ice-cold Hanks' balanced salt solution (HBSS) and resuspended in 1 
ml of HBSS. Cells (2- 2.5 X 106) were radioiodinated with 1 mCi of 
[1 25l] sodium (New England Nuclear, Boston, Massachusetts) in the 
presence of 0.5 mg of lactoperoxidase and 0.025 ml of 0.03% hydrogen 
peroxide in phosphate-buffered saline (PBS). Additional 0.025-ml a li· 
quots of 0.03 % hydrogen peroxide were added at 3-min intervals. After 
10 min the cells were washed 4 times with 50 ml of cold HBSS with 10 
mM Nai and 5 mM tyrosine. Cell viability fo llowing radioiodination 
was 90- 95% as de te rmined by trypan blue exclusion. Labeled macro-
molecules were solubilized by lysing the cells in 1.0 ml of 0.5% NP-40 
(Nonidet P -40, Shell Chemical Corp., New York, New York) in PBS 
for 1 h at 4 ·c. Insoluble material was removed by centrifugation at 
12,000 g for 20 min. Precipitation with 10% trichloroacetic acid was 
used to measure radioactivity associated with acid-insoluble macro-
molecules. 
Antibody Assay 
Antibodies to melanocytes were measured by specific immunopreci-
pitation with protein A-sepharose. Radioiodinated cell lysate (0.1 ml 
undiluted) was incubated at 4 ·c with equal volumes of sera (diluted 
1:10 with PBS, pH 7.4) and 0.2 ml of 0.5 % NP-40. After 12 h, 0.02 ml 
of protein A-sepharose (Pharmacia Inc., Piscataway, New Jersey) di· 
luted with PBS 1:1, was added to all tubes. Samples were agitated 
continuously for 2 h at 4 ·c and centrifuged at 2000 g for 3 min in a 
microfuge. Pellets were washed 4 times with 0.2 ml of 0.5 % NP-40 in 
PBS and radioactivity was determined on a Searle 1185 gamma counter. 
All assays were performed in duplicate. Equal volumes of radioiodinated 
cell lysate and PBS were incubated with protein A-sepharose in a 
manner identical to the assay with vitiligo and norm.a l sera to preclude 
the possibility of nonspecific cell membrane interac tion with the se-
pharose. Specific binding was calculated by subtracting from the aver· 
age cpm bound by the test serum the cpm bound by an equal volume 
of a normal human serum. The same norma l serum was used as a 
baseline in all studies. Radioactivity associated with ac id-insoluble 
mac romolecules was measured by precipitation with 10 trichloroacetic 
acid [1 3]. Percent specific binding was calculated from: 
Specific cpm bound by test se ra 
0 ~~~~~----~~~~x 10 
TCA· insoluble cpm in sample 
RESULTS 
Sera from 12 patients with common viti ligo and 12 individ-
uals with .nonpigmentary diseases were tested for binding activ-
ity to soluble, radioiodinated macromolecules of human melan-
ocytes and control cells by specific immunoprecipitation. The 
results are summarized in Table I. In every instance vitiligo 
sera bound considerably more labeled melanocyte macromole-
cules (as illustrated in cpm) than did equal volumes of normal 
human test sera. Values of binding with the normal control 
serum are found in Table I. On the average, the vitiligo sera 
bound specifica lly 6.5% (range 3.1-9.4) of the radioactivity 
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T ABLE I. Binding of radioiodinated macromolecules of melanocytes and control cells by sera a( vitiligo and normal patients 
Binding of surface macro molecules 
Diagnosis Sera Melanocyte• Melanoma' Fibrob last' no. 
cpmlf % TCN cpm % TCA cp m % T CA 
Vit iligo 1 11,270 4 ± 0.581 1,459 0.04 2,186 0 
2 15,061 7.4 ± 1.02 1,834 0.08 1,519 0 
3 14,635 6.9 ± 0.38 1,463 0 1,346 0 
4 10,602 3.1 ± 0.24 2,912 1.1 2,839 0.08 
5 19,778 9.4 ± 2.52 5,123 2.7 2,701 0 
6 13,526 6.1 ± 2.56 964 0 2,719 0.05 
7 18,530 8.5 ± 0.8 1,049 0 1,764 0 
8 11,086 4.2 ± 0.95 3,160 1.6 1,460 0 
9 14,968 7.3 ± 1.64 1,364 0 1,597 0 
10 17,950 8.5 ± 1.3 1,430 0 2,206 0 
11 13,464 6.0 ± 0.72 2,901 0.9 1,943 0 
12 13,941 6.1 ± 0.76 2,899 0.8 3,040 0.1 
Average 14,509 6.46 ± 1.12 2,213.2 0.60 2,110 0.036 
Normal 13 2,579 0.4 ± 0.32 1,261 0 1,930 0.3 
14 4,430 1.21 ± 0.8 3,999 1.4 1,724 0 
15 1,034 0±0 1,865 0.2 3,181 0.6 
16 3,173 0.9 ± 0.3 2,802 0.6 3,837 0.8 
17 1,949 0±0 1,744 0 1,753 0 
18 2,740 0.6 ± 0.26 3,243 0.8 2,160 0.4 
19 2,946 0.7 ± 0. 10 1,430 0 957 0 
20 2,990 0.7 ± 0.14 3,010 1.4 1,007 0 
21 1,940 0 ± 0 1,957 0.4 ~,907 0.3 
22 3,193 0.9 ± 0.8 2,130 0.5 1,049 0 
23 1,650 0±0 3,874 0.2 973 0 
24 4,097 1.2 ± 0 1,863 0.3 1,897 0.2 
Average 2,726.7 0.56 ± 0.26 2,430.7 0.57 1,864.6 0.23 
Normal serum 1,430 1,306 1,760 
PBS 231 105 115 
• NP-40 cell lysate, 108,656 T CA-insoluble CPM per 0.1 mi. 
• NP-40 cell lysate , 97,940 T CA -insoluble CPM per 0.1 mi. 
' N P-40 cell lysate, 57,941 TCA- insoluble CPM per 0. 1 mi. 
" Im mu noprecipi tated by 10 A of sera (in cpm). 
• Percent TCA-insoluble cpm bound specifically by 10 A sera. Calculated as desc ribed in Methods. 
I Standard erro r of the mea n. 
associated with labeled melanocyte macromolecules, whereas 
t he 12 normal se ra bound only 0.56% (range 0- 1.2). This 
difference is significant (p < 0.05). Adding t he binding values 
of t he normal cont rol serum to t he data from both vit iligo and 
normal sera does not alter t he s ignificance of the results. By 
cont rast, vi t iligo and normal sera bound similarly and to a low 
extent radioiodinated macromolecules of normal human fibro-
blasts and malignant melanoma cells. T his finding suggests 
t hat t he binding activity in vit iligo se ra is specific for melano-
cytes and is not t he result of circulating immune complexes or 
other nonspec ific factors in t hese sera. 
The results of t he assay were both reproducible and quant i-
tative. As illustrated in T able II, variations between replicate 
samples of se ra tested against t he same melanocyte lysate on 
t he same day (columns A and B) , different days (column C), or 
against melanocyte lysates prepared fro m two di ffe rent individ-
uals (column D ) was ± 20%. By analysis of variance using a 
two-way factorial design t hese were highly reproducible results. 
There was a linear relat ionship between the di lut ion of vit ili go 
serum used in the assay and specifically bound radioactivity, 
suggesting t hat t he assay provides a quant itative measure of 
antibodies to melanocyte-associated ant igens. 
DISCUSSIO N 
Results from t his study suggest t hat patients with active, 
common vit iligo have antibodies to surface ant igens of normal 
human melanocytes and t hat t hey can be detected by specific 
immunoprecipitation. T hese antibodies do not react with hu -
man melanoma cells and t hey were not found in t he normal 
human sera we examined. 
Whi le t he cause of vit il igo is present ly not known, it is 
believed t hat immune mechanisms may be involved in its 
pathogenesis. Repeated attempts to demonstrate abnormal it ies 
in humora l and/or cellular immunity in vi t iligo have fa iled in 
t he past. Recent ly, it has been reported that 4 patients with 
vit iligo had complement-fixing antibodies to melanocytes [5-
7]. All 4 patients also had MCC. A subsequent study of a much 
larger number of vi t iligo patients revealed t hat t hese antibodies 
were associated with MCC rather than vit iligo [9]. 
T he recent development of methods to grow human melan-
ocytes in culture allowed us to apply a sensit ive and quantitative 
ant ige n-binding assay to t he study of melanocyte an tibodies. 
This assay has been used successfully to measure antibodies to 
melanoma in patients wit h t his cancer [8]. Using t his approach 
we have found t hat patien ts wit h active, common vit il igo have 
ant ibodies to melanocytes. T hese ant ibodies appear to be di-
rected to surface ant igen (s) or melanocytes since surface mac-
romolecules are radioiodinated by t he lactoperox idase tech-
nique, a method which labels only external components of 
viable cells [11] . The ant igen (s) appears to be melanocyte 
associated s ince ant ibodies to it do not react with normal 
human fibroblasts or wi th human melanoma cells. 
In conclusion, t his ini t ial study in a small nu mber of patients 
suggests t hat active , common vit iligo is associated with anti-
bodies to melanocytes. It is attractive to interpret t his findi ng 
to mean that vit iligo is mediated by ant ibodies to melanocyte-
associated cell -surface ant igen (s) . However, we have not ex-
cluded the fact t hat t he antibodies are a resu lt, rather t han a 
cause, of vit iligo or t hat other mechanisms also play a role in 
t he pathogenesis of t hi s unusual disease. 
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TABLE II. Reproducibility of specific immunoprecipitation assay for 
melanocyte antibodies" 
% TCA -insoluble cpm bound spec ifica lly 
Diagnos is Sera Melanocyte lyRate 1 Melanocyte lysate 2 
A• s• C' Dd 
Viti ligo 1 4.3 3.7 2.9 4.1 
2 7.9 6.9 6.4 5.3 
3 6.7 7. 1 5.8 4.9 
4 3.2 3.0 3.1 4.3 
5 8.1 11.0 9.1 8.7 
6 7.4 4.8 5.9 5.6 
7 8.9 8. 1 8.1 6.3 
8 3.7 4.7 3.9 5.1 
9 6.5 8.1 6.4 6.4 
10 7.9 9.2 7.1 7.4 
11 6.4 5.7 5.7 8.6 
12 5.7 6.5 5.4 6.6 
Average 6.4 6.5 5.8 6.1 
Norma l 13 0.5 0.2 0.4 0 
14 1.6 0.8 1.2 0.8 
15 0 0 0 0.2 
16 0.7 1.1 0.6 0.6 
17 0 0 0 0 
18 0.4 0.7 0.3 0 
19 0.8 0.7 0.6 0.6 
20 0.6 0.7 0.6 0.2 
21 0 0 0 0.3 
22 0.5 1.3 0.9 0.6 
23 0 0 0 0 
24 1.8 0.6 0.8 0 
Average 0.57 0.51 0.48 0. 27 
" By analysis of va riance using a two-way factorial design. 
• Rep licate samples of lysate 1 tested on t he same day; 108,656 TCA-
insolu ble cpm per 0. 1 ml ce ll lysate. 
' Assay using mela nocyte lysate 1 a fter 1-week interval; 94,410 TCA -
inso luble cpm per 0.1 ml ce ll lysate. 
d Assay using melanocyte lysate 2, prepared from a different individ-
ua l; 91,380 TCA- insoluble cpm per 0. 1 ml cell lysate. 
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